BOT17X-i: Oncoloscan, diagnostic 68Gallium PET-imaging and BOT17X-t: Oncoluthera, targeted 177Lutetium radiotherapy

BOT17X is a high affinity PDGF-ß-receptor binding VHH nanobody NOTA conjugate.

 

Binding to and accumulation of BOT17X in PDGF-ß-receptor overexpressing cells has demonstrated to be disease-specific with functional signal/background ratios in the fibrotic liver and in primary and metastasized CMS4 colorectal cancer.

 

 

In the imaging diagnostic BOT17X-i, Oncoloscan®, the PET radionuclide 68Gallium is conjugated to the PDGF-ß-receptor binding VHH nanobody.

In the targeted radiotherapeutic BOT17X-t, Oncoluthera ® the PET radionuclide 177Lutetium is conjugated to the PDGF-ß-receptor binding VHH nanobody.